Zimmer Biomet Holdings (ZBH, Health Care Equipment) Stock Valuation & Fair Value Fairly valued
Zimmer Biomet Holdings (ZBH, Health Care Equipment) trades at a blended P/E of 11.8, about 25% below its historical normal valuation, with a forward growth estimate of 6.2% and a PEG of 1.90. Analysts' one-year estimates have been hit 82% of the time.
The Street vs SeerForecast
Wall Street's mean price target for ZBH is $107.57 across 21 analysts, 6.5% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: fairly valued. When the two disagree, start your digging there.
Valuation flags
- No notable valuation flags.
Verdict history
tickerseer's rating has been fairly valued since 2026-06-03.
Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.
Frequently asked questions
Is Zimmer Biomet Holdings stock overvalued?
At a blended P/E of 11.8 versus its historical normal P/E of 15.7, Zimmer Biomet Holdings trades about 25% below its typical valuation, with a PEG of 1.90 on 6.2% forward growth. tickerseer currently rates it fairly valued.
What is Zimmer Biomet Holdings's fair value and PEG?
Zimmer Biomet Holdings trades at a blended P/E of 11.8 against a historical normal P/E of 15.7, a PEG of 1.90, and a forward growth estimate of 6.2%.
Has tickerseer's rating of Zimmer Biomet Holdings changed?
tickerseer's rating has been fairly valued since 2026-06-03.
What is the analyst price target for Zimmer Biomet Holdings?
The mean Wall Street price target for Zimmer Biomet Holdings is $107.57 across 21 analysts, 6.5% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Health Care Equipment. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. Educational content, not investment advice.